{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:09:34Z","timestamp":1789196974937,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"DOI":"10.1007\/s11655-026-4048-5","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:03Z","timestamp":1789194423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis"],"prefix":"10.1007","author":[{"given":"Jing-min","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-zhe","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-huang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-xin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-liang","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-bo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"4048_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","volume":"17","author":"D Capodanno","year":"2020","unstructured":"Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Gibson CM, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol 2020;17:242\u2013257.","journal-title":"Nat Rev Cardiol"},{"key":"4048_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.003901","volume":"132","author":"PM Cirillo","year":"2015","unstructured":"Cirillo PM, Cohn BA. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation 2015;132:1234\u20131242.","journal-title":"Circulation"},{"key":"4048_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjmed.2017.01.002","volume":"130","author":"PR Kalra","year":"2017","unstructured":"Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendera M, et al. Hemoglobin and change in hemoglobin status predict mortality, cardiovascular events, and bleeding in stable coronary artery disease. Am J Med 2017;130:720\u2013730.","journal-title":"Am J Med"},{"key":"4048_CR4","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41598-023-28029-w","volume":"13","author":"WJ Lee","year":"2023","unstructured":"Lee WJ, Choi S, Park SM, Lee G, Chang J, Oh YH, et al. Association of hemoglobin variability with the risk of cardiovascular disease: a nationally representative retrospective cohort study from South Korea. Sci Rep 2023;13:2148.","journal-title":"Sci Rep"},{"key":"4048_CR5","first-page":"2525","volume":"117","author":"P Libby","year":"2021","unstructured":"Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res 2021;117:2525\u20132536.","journal-title":"Cardiovasc Res"},{"key":"4048_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","volume":"30","author":"J Hoshino","year":"2020","unstructured":"Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3\u20135 nondialysis CKD. J Ren Nutr 2020;30:404\u2013414.","journal-title":"J Ren Nutr"},{"key":"4048_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-024-00988-1","volume":"21","author":"S Lakhal-Littleton","year":"2024","unstructured":"Lakhal-Littleton S, Cleland JGF. Iron deficiency and supplementation in heart failure. Nat Rev Cardiol 2024:21:463\u2013486.","journal-title":"Nat Rev Cardiol"},{"key":"4048_CR8","doi-asserted-by":"publisher","first-page":"e003019","DOI":"10.1161\/JAHA.115.003019","volume":"5","author":"RS Barlas","year":"2016","unstructured":"Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, et al. Impact of hemoglobin levels and anemia on mortality in acute stroke: analysis of UK regional registry data, systematic review, and meta-analysis. J Am Heart Assoc 2016;5:e003019.","journal-title":"J Am Heart Assoc"},{"key":"4048_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2014.09.010","volume":"169","author":"IT Klip","year":"2015","unstructured":"Klip IT, Postmus D, Voors AA, Brouwers FP, Gansevoort RT, Bakker SJ, et al. Hemoglobin levels and new-onset heart failure in the community. Am Heart J 2015;169:94\u2013101.e2.","journal-title":"Am Heart J"},{"key":"4048_CR10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.4244\/EIJ-D-21-00415","volume":"17","author":"H Hara","year":"2022","unstructured":"Hara H, Kawashima H, Ono M, et al. Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. EuroIntervention 2022;17:1477\u20131487.","journal-title":"EuroIntervention"},{"key":"4048_CR11","doi-asserted-by":"publisher","first-page":"e007723","DOI":"10.1161\/JAHA.117.007723","volume":"7","author":"G Lee","year":"2018","unstructured":"Lee G, Choi S, Kim K, Yun JM, Son JS, Jeong SM, et al. Association of hemoglobin concentration and its change with cardiovascular and all-cause mortality. J Am Heart Assoc 2018;7:e007723.","journal-title":"J Am Heart Assoc"},{"key":"4048_CR12","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/eurheartj\/ehae284","volume":"45","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, et al. Identification of three mechanistic pathways for irondeficient heart failure. Eur Heart J 2024;45:2281\u20132293.","journal-title":"Eur Heart J"},{"key":"4048_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2015.03.159","volume":"186","author":"G Kaiafa","year":"2015","unstructured":"Kaiafa G, Kanellos I, Savopoulos C, Kakaletsis N, Giannakoulas G, Hatzitolios AI. Is anemia a new cardiovascular risk factor? Int J Cardiol 2015;186:117\u2013124.","journal-title":"Int J Cardiol"},{"key":"4048_CR14","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","volume":"69","author":"P Hao","year":"2017","unstructured":"Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol 2017;69:2952\u20132966.","journal-title":"J Am Coll Cardiol"},{"key":"4048_CR15","doi-asserted-by":"publisher","first-page":"751050","DOI":"10.3389\/fphar.2021.751050","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Shan Y, Sun W, Han J, Tong H, Fan M, et al. Effects of Shexiang Baoxin Pill for coronary microvascular function: a systematic review and meta-analysis. Front Pharmacol 2021:12:751050.","journal-title":"Front Pharmacol"},{"key":"4048_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jep.2016.11.024","volume":"194","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Shen W, Yu L, Xu C, Wu Q. A Chinese patent medicine, Shexiang Baoxin Pill, for non-ST-elevation acute coronary syndromes: a systematic review. J Ethnopharmacol 2016;194:1130\u20131139.","journal-title":"J Ethnopharmacol"},{"key":"4048_CR17","doi-asserted-by":"publisher","first-page":"43632","DOI":"10.1038\/srep43632","volume":"7","author":"HY Fang","year":"2017","unstructured":"Fang HY, Zeng HW, Lin LM, Chen X, Shen XN, Fu P, et al. A network-based method for mechanistic investigation of Shexiang Baoxin Pill\u2019s treatment of cardiovascular diseases. Sci Rep 2017;7:43632.","journal-title":"Sci Rep"},{"key":"4048_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jchromb.2014.07.038","volume":"967","author":"S Wang","year":"2014","unstructured":"Wang S, Peng C, Jiang P, Fu P, Tao J, Han L, et al. Simultaneous determination of seven bufadienolides in rat plasma after oral administration of Shexiang Baoxin Pill by liquid chromatography-electrospray ionization-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2014;967:255\u2013263.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4048_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jchromb.2014.05.047","volume":"963","author":"W Chang","year":"2014","unstructured":"Chang W, Han L, Huang H, Wen B, Peng C, Lv C, et al. Simultaneous determination of four volatile compounds in rat plasma after oral administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GC-MS\/MS and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2014;963:47\u201353.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4048_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CM9.0000000000001257","volume":"134","author":"JB Ge","year":"2021","unstructured":"Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, et al. Efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial. Chin Med J 2021;134:185\u2013192.","journal-title":"Chin Med J"},{"key":"4048_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/CM9.0000000000002527","volume":"136","author":"J Zhou","year":"2023","unstructured":"Zhou J, Shi H, Ji F, Wu Y, Zhao Y, Qian J, et al. Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial. Chin Med J 2023;136:82\u201387.","journal-title":"Chin Med J"},{"key":"4048_CR22","doi-asserted-by":"publisher","first-page":"106506","DOI":"10.1016\/j.ejim.2025.106506","volume":"143","author":"J Heng","year":"2026","unstructured":"Heng J, Li ZT, Yao DD, Li XY, Cui MX, Li ZL. Anemia in cardiorenal disease: from pathogenesis to treatment. Eur J Intem Med 2026:143:106506.","journal-title":"Eur J Intem Med"},{"key":"4048_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fphar.2018.01161","volume":"9","author":"L Lu","year":"2018","unstructured":"Lu L, Sun X, Chen C, Qin Y, Guo X. Shexiang Baoxin Pill, derived from the traditional Chinese medicine, provides protective roles against cardiovascular diseases. Front Pharmacol 2018;9:1161.","journal-title":"Front Pharmacol"},{"key":"4048_CR24","doi-asserted-by":"publisher","first-page":"7644648","DOI":"10.1155\/2021\/7644648","volume":"2021","author":"J Guo","year":"2021","unstructured":"Guo J, Qin Z, He Q, Fong TL, Lau NC, Cho WCS, et al. Shexiang Baoxin Pill for acute myocardial infarction: clinical evidence and molecular mechanism of antioxidative stress. Oxid Med Cell Longev 2021;2021:7644648.","journal-title":"Oxid Med Cell Longev"},{"key":"4048_CR25","doi-asserted-by":"publisher","first-page":"665456","DOI":"10.3389\/fphar.2021.665456","volume":"12","author":"ZS Qin","year":"2021","unstructured":"Qin ZS, Zheng Y, Zhou XD, Shi DD, Cheng D, Shek CS, et al. Shexiang Baoxin Pill, a proprietary multi-constituent Chinese medicine, prevents locomotor and cognitive impairment caused by brain ischemia and reperfusion injury in rats: a potential therapy for neuropsychiatric sequelae of stroke. Front Pharmacol 2021;12:665456.","journal-title":"Front Pharmacol"},{"key":"4048_CR26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.7150\/ijms.85789","volume":"20","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Song Z, Fan Y, Lin S, Ge Z, et al. Chinese patent medicines for coronary microvascular disease: clinical evidence and potential mechanisms. Int J Med Sci 2023;20:1024\u20131037.","journal-title":"Int J Med Sci"},{"key":"4048_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fphar.2020.00422","volume":"11","author":"A Shaito","year":"2020","unstructured":"Shaito A, Thuan DTB, Phu HT, Nguyen THD, Hasan H, Halabi S, et al. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety. Front Pharmacol 2020;11:422.","journal-title":"Front Pharmacol"},{"key":"4048_CR28","doi-asserted-by":"publisher","first-page":"e0299236","DOI":"10.1371\/journal.pone.0299236","volume":"19","author":"J Pan","year":"2024","unstructured":"Pan J, Ping PD, Wang W, Zhou JM, Zhu WT. Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China. PLoS One 2024;19:e0299236.","journal-title":"PLoS One"},{"key":"4048_CR29","first-page":"55","volume":"13","author":"RA Byrne","year":"2024","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J Acute Cardiovasc Care 2024;13:55\u2013161.","journal-title":"Eur Heart J Acute Cardiovasc Care"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-026-4048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-026-4048-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-026-4048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:04Z","timestamp":1789194424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-026-4048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":29,"alternative-id":["4048"],"URL":"https:\/\/doi.org\/10.1007\/s11655-026-4048-5","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"8 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by the Shanghai Science and Technology Committee and Shanghai Hutchison Pharmaceuticals Company. The funders had no role in the study design, collection, analysis and interpretation of data, the writing of the manuscript, or the decision to submit the article for publication. The authors declare no other conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}